Search - tctmd.com

Displaying 321 - 334 of 334

Sort: Relevancy | Date

Presentation EuroPCR 2013

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Presenter: Sigmund Silber

May 22, 2013

Presentation

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

Presenter: K. Tandjung

April 26, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

Presentation PCI Outcomes 2013

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Presenter: C. Michael Gibson

March 07, 2013

Presentation

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Presenter: Suresh R. Mulukutla

December 05, 2012

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Presentation TCT 2012

What Evidence Is Necessary to Shorten DAPT After DES?

Presenter: Fausto Feres

October 25, 2012

Presentation TCT 2012

Proposals for New Short-Term DAPT Use Trials After DES

Presenter: Roxana Mehran

October 25, 2012

Presentation TCT 2012

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

Presenter: David Kandzari

October 22, 2012

Presentation TCT 2012

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

Presenter: Roxana Mehran

October 22, 2012

Presentation TCT 2012

DAPT Trial Update

Presenter: Laura Mauri

October 22, 2012

Presentation

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Presenter: T. Tada

June 01, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

Advertisement

The Unplanned DAPT Discontinuation Patient: How Can I Make Informed Decisions?

Clinical Outcome Following Discontinuation of DAPT After 12 months in Real-World Patients Treated with Second-Generation ZES and EES

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

DAPT + Oral Anticoagulation: Indications and Risk Amelioration

Benefit of Long-term Dual Antiplatelet Therapy (DAPT) in Patients Treated with DES

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

What Evidence Is Necessary to Shorten DAPT After DES?

Proposals for New Short-Term DAPT Use Trials After DES

Rationale and Data for Different DAPT Durations: From 3 to 30 Months (or Longer)

PARIS 1-Year: Impact of DAPT Cessation and Non-adherence on Adverse Events Following PCI

DAPT Trial Update

Duration of DAPT and Long-term Clinical Outcome After Coronary DES Implantation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content